FrancophonIA/ELRC3.0 huggingface dataset:
English: Rapinyl should only be administered with extreme caution in patients who may be particularly susceptible to the intracranial effects of hyperkapnia, such as those showing evidence of raised intracranial pressure, reduced consciousness, coma or brain tumours.
Estonian: Patsientidele, kes on eriti tundlikud CO2 retentsiooni intrakraniaalset toimete suhtes (tõusnud intrakraniaalse rõhu sümptomitega-, teadvushäiretega-, kooma ja ajuvähiga patsiendid), tohib Rapinyl'i manustada ainult äärmise ettevaatlikkusega.
English: Rapinyl 600 microgram sublingual tablets
Estonian: Rapinyl 600-mikrogrammised subligvaalsed tabletid
English: Before Rapinyl therapy is initiated, it is important that the patient's long-acting opioid treatment used to control their persistent pain has been stabilised.
Estonian: On tähtis, et püsiva valu raviks kasutatavate pikatoimeliste opioidide annused oleksid stabiilised enne Rapinyl'iga ravi alustamist.
English: If patients are switched from another fentanyl containing product, a new dose titration with Rapinyl is required.
Estonian: Kui üleminek toimub teiselt fentanüüli sisaldavalt preparaadilt, tuleb Rapinyl'i annust tiitrida eelmisest preparaadist sõltumatult.
English: Rapinyl 100 microgram sublingual tablets
Estonian: Rapinyl 100-mikrogrammised subligvaalsed tabletid
English: Your doctor will prescribe the strength (shape) and number of tablets suitable for you.
Estonian: Teie arst määrab teile sobiva tableti tugevuse (kuju) ja arvu.
English: Store in the original blister package in order to protect from moisture It is recommended to keep Rapinyl in a locked storage space
Estonian: Rapinyl'i soovitame hoida lukustatud kapis
English: Whereas
Estonian: KÕLBLIKKUSAEG
English: EU (MA) Number
Estonian: EL (ML) number
English: Annex I List of the names, pharmaceutical form, strengths of the medicinal products, route of administration, Marketing Authorisation Holders in the Member States
Estonian: I Lisa Ravimite nimetuste, ravimvormide, tugevuste, manustamisviiside, taotlejate, müügiloa hoidjate loetelu liikmesriikides
English: Netherlands Sanofi-Aventis Netherlands B.V.
Estonian: Sanofi-Aventis Netherlands B.V.
English: Five main studies were carried out.
Estonian: Tehti viis põhiuuringut.
English: However, the duration of protection is not known.
Estonian: Kaitse kestus ei ole teada.
English: Further information on Imvanex can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/imvanex.
Estonian: Lisateave Imvanexi kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/imvanex.
English: Smallpox was officially declared eradicated in 1980 with the last known case of the disease occurring in 1977.
Estonian: Rõuged kuulutati 1980. aastal ametlikult likvideeritud haiguseks ning viimane teadaolev haigusjuht leidis aset 1977. aastal.
English: Imvanex received a marketing authorisation valid throughout the EU on 31 July 2013.
Estonian: Imvanex on saanud müügiloa, mis kehtib kogu ELis, 31. juulil 2013.
English: What measures are being taken to ensure the safe and effective use of Imvanex?
Estonian: Mis meetmed võetakse, et tagada Imvanexi ohutu ja efektiivne kasutamine?
English: Since Imvanex has been authorised under exceptional circumstances, the company that markets Imvanex will provide data on the vaccine's benefits and risks from observational studies in patients who are given the vaccine, and if ever there is an outbreak of the disease in the future.
Estonian: Et Imvanex on saanud müügiloa erandlikel asjaoludel, esitab Imvanexi turustaja andmed vaktsiini kasu ja riskide kohta vaktsineeritud patsientidel tehtud jälgimisuuringutest ja kui kunagi tulevikus tekib haiguse puhang.
English: It is not yet known how long the protection will last.
Estonian: Kaitse püsimise kestus ei ole veel teada.
English: As for all medicines, data on the use of Imvanex are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, tehakse Imvanexi kasutamise kohta pidevat järelevalvet.
English: Imvanex (live modified vaccinia ankara virus)
Estonian: Imvanex (modifitseeritud vaccinia Ankara elusviirus)
English: The most common side effects with Imvanex (which may affect more than 1 in 10 people) are headache, nausea, myalgia (muscle pain), tiredness and injection site reactions (pain, redness, swelling, hardening and itching).
Estonian: Imvanexi kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 inimesel 10st) on peavalu, iiveldus, müalgia (lihasevalu), väsimus ja süstekoha reaktsioonid (valu, punetus, turse, kõvenemine ja sügelus).
English: When the person comes into contact again with this or a similar virus, these antibodies together with other components of the immune system will be able to kill the viruses and help protect against the disease.
Estonian: Kui inimene puutub selle või mõne sarnase viirusega hiljem uuesti kokku, hävitavad need antikehad koos immuunsüsteemi teiste osadega viiruse ning aitavad kaitsta haiguse eest.
English: What is Imvanex and what is it used for?
Estonian: Mis on Imvanex ja milleks seda kasutatakse?
English: Other information about Imvanex
Estonian: Muu teave Imvanexi kohta
English: Vaccines containing vaccinia viruses were effective in the campaign to eradicate smallpox.
Estonian: Vaktsiiniaviirusi sisaldavad vaktsiinid olid edukad rõugete likvideerimise kampaanias.
English: Why is Imvanex authorised in the EU?
Estonian: Miks Imvanex ELis heaks kiideti?
English: Side effects reported with Imvanex are carefully evaluated and any necessary action taken to protect patients.
Estonian: Imvanexi kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks võetakse vajalikke meetmeid.
English: This vaccine will be used when it is considered necessary to protect against smallpox in accordance with official recommendations.
Estonian: Vaktsiini kasutatakse juhul, kui ametlike soovituste kohaselt on vajalik kaitse rõugete eest.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Imvanex have been included in the summary of product characteristics and the package leaflet.
Estonian: Imnavexi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: This is because it has not been possible to obtain complete information about Imvanex due to the rarity of the disease.
Estonian: See tähendab, et harvaesineva haiguse tõttu ei olnud võimalik saada Imvanexi kohta täielikku teavet.
English: For more information about using Imvanex, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet kasutamise kohta saate pakendi infolehelt või küsige oma arstilt või apteekrilt.
English: Imvanex would therefore be beneficial for people who cannot be given vaccines containing replicating viruses, such as patients with a weakened immune system.
Estonian: Imvanex on seetõttu kasulik neile, kellele ei saa manustada paljunevaid viirusi sisaldavaid vaktsiine, näiteks nõrgestatud immuunsüsteemiga inimestele.
English: The studies involved over 2,000 adults, including patients with HIV and atopic dermatitis (an itchy skin condition caused by an overactive immune system) and people who had been vaccinated against smallpox in the past.
Estonian: Uuringutes osales üle 2000 täiskasvanu, sh HIVi ja atoopilise dermatiidiga (liigaktiivsest immuunsüsteemist tingitud sügelev nahahaigus) patsiendid ning varem rõugete vastu vaktsineeritud inimesed.
English: Imvanex has been authorised under ‘exceptional circumstances'.
Estonian: Imvanex on saanud müügiloa erandlikel asjaoludel.
English: Imvanex contains a modified form of the vaccinia virus called vaccinia Ankara, which does not cause disease in humans and cannot replicate (reproduce) in human cells.
Estonian: Imvanex sisaldab vaktsiiniaviiruse modifitseeritud vormi „vaccinia Ankara“, mis ei põhjusta inimestel haigestumist ega suuda inimrakkudes paljuneda.
English: Two of the studies specifically looked at the effectiveness of Imvanex as a booster.
Estonian: Kahes uuringus uuriti spetsiaalselt Imvanexi kui kordusvaktsiini efektiivsust.
English: Imvanex must not be used in patients who are hypersensitive (allergic) to the active substance or any of the substances found at trace levels, such as chicken protein, benzonase and gentamicin.
Estonian: Imvanexi ei tohi kasutada patsiendid, kes on vaktsiini toimeaine või vaktsiinis mikrokogustes sisalduvate ainete, näiteks kanavalgu, bensonaasi ja gentamütsiini suhtes allergilised (ülitundlikud).
English: The vaccinia virus in Imvanex cannot replicate in human cells and hence is less likely to cause side effects than conventional smallpox vaccines.
Estonian: Imvanexis sisalduv vaktsiiniaviirus ei suuda inimrakkudes paljuneda ning põhjustab seetõttu tõenäoliselt vähem kõrvalnähte kui tavapärased rõugevaktsiinid.
English: It contains a live modified form of the vaccinia virus called ‘vaccinia Ankara', which is related to the smallpox virus.
Estonian: See sisaldab modifitseeritud vaktsiinia elusviirust „vaccinia Ankara“, mis on seotud rõugeviirusega.
English: What information is still awaited for Imvanex?
Estonian: Mis teavet Imvanexi kohta veel oodatakse?
English: If a booster dose is necessary for those who have been vaccinated against smallpox in the past, a single 0.5 ml dose should be given except for patients with a weakened immune system (the body's natural defences) who should receive two booster doses, with the second dose given at least 28 days after the first.
Estonian: Kui varem rõugete vastu vaktsineeritud patsiendid vajavad revaktsineerimist, tuleb manustada üks 0,5 ml annus, v.a nõrgenenud immuunsüsteemiga (organismi loodusliku kaitsemehhanismiga) patsiendid, kes peavad saama kaks kordusannust, millest teine annus tuleb manustada vähemalt 28 päeva pärast esimest.
English: Imvanex is a vaccine used to protect against smallpox in adults.
Estonian: Imvanex on vaktsiin, millega kaitstakse täiskasvanuid rõugete eest.
English: What are the risks associated with Imvanex?
Estonian: Mis riskid Imvanexiga kaasnevad?
English: A subsequent study in 433 people who had not been vaccinated before found that the level of protective antibodies after vaccination with Imvanex was at least as high as with a conventional smallpox vaccine.
Estonian: 433 varem vaktsineerimata inimesel tehtud järeluuringus leiti, et Imvanexiga vaktsineerimise järel tekkinud antikehade sisaldus oli vähemalt sama suur nagu tavapärase rõugevaktsiini kasutamisel.
English: The European Medicines Agency considered that Imvanex is effective at triggering the production of antibodies against smallpox to a level that provides protection at least as high as that from conventional smallpox vaccines.
Estonian: Euroopa Ravimiamet otsustas, et Imvanex on efektiivne rõugevastaste antikehade tekitamisel tasemel, mis tagab vähemalt sama hea kaitse nagu tavapärased rõugevaktsiinid.
English: Vaccines work by ‘teaching' the immune system how to defend itself against a disease.
Estonian: Vaktsiinid n-ö õpetavad immuunsüsteemi (organismi looduslikke kaitsemehhanisme) kaitsma organismi haiguse eest.
English: How does Imvanex work?
Estonian: Kuidas Imvanex toimib?
English: Because of its similarity to the smallpox virus, antibodies produced against this virus are also expected to protect against smallpox.
Estonian: Tänu sarnasusele rõugeviirusega kaitsevad selle viiruse vastu tekkinud antikehad inimest eeldatavalt ka rõugete eest.
English: When a person is given the vaccine, the immune system recognises the virus in the vaccine as ‘foreign' and makes antibodies against it.
Estonian: Vaktsiini manustamisel peab immuunsüsteem vaktsiinis sisalduvat viirust võõraks ja tekitab selle vastu antikehi.
English: An overview of Imvanex and why it is authorised in the EU
Estonian: Ülevaade ravimist Imvanex ja ELis müügiloa väljastamise põhjendus
English: Imvanex was shown in studies to be effective at triggering the production of antibodies to a level expected to provide protection against smallpox.
Estonian: Uuringutes tõendati Imvanexi efektiivsust antikehade tekitamisel tasemel, mis eeldatavasti kaitseb rõugete eest.
English: How is Imvanex used?
Estonian: Kuidas Imvanexi kasutatakse?
English: What benefits of Imvanex have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Imvanexi kasulikkus?
English: Imvanex is given by injection under the skin, preferably in the upper arm. People who have not been previously vaccinated against smallpox should receive two 0.5 ml doses, with the second dose given at least 28 days after the first.
Estonian: Varem rõugete vastu vaktsineerimata patsiendid peavad saama kaks 0,5 ml annust; teine annus tuleb manustada vähemalt 28 päeva pärast esimest.
English: • Bioequivalence vis-à-vis an EU reference medicinal product has been demonstrated, based on relevant data, in accordance with the requirements of Article 10 of Directive 2001/83/EC (e.g. a bioequivalence study conducted vis-à-vis the EU reference medicinal product).
Estonian: • Bioekvivalentsus Euroopa Liidu võrdlusravimiga on tõendatud asjakohaste andmete alusel kooskõlas direktiivi 2001/83/EÜ artikliga 10 (nt Euroopa Liidu võrdlusravimiga bioekvivalentsuse uuring).
English: For the suspension of the marketing authorisations referred to in annex IB to be lifted, the competent authorities of the EU Member States shall ensure that the below condition has been completed by the marketing authorisation holder(s)
Estonian: IB lisas viidatud müügilubade peatamise lõpetamiseks peavad Euroopa Liidu liikmesriikide pädevad asutused tagama, et müügiloa hoidjad on täitnud järgmised tingimused.
English: Condition for lifting the suspension of the marketing authorisations
Estonian: Müügilubade peatamise lõpetamise tingimused
English: It is available as tablets (15, 30 and 45 mg).
Estonian: Seda turustatakse tablettidena (15, 30 ja 45 mg).
English: This summary was last updated in 10-2011.
Estonian: Kokkuvõtte viimane uuendus: 10-2011
English: The European Commission granted a marketing authorisation valid throughout the European Union for Sepioglin on 9 March 2012.
Estonian: Euroopa Komisjon andis Sepioglini müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 9. märtsil 2012.
English: The tablets should be swallowed with water.
Estonian: Tabletid tuleb neelata koos veega.
English: The full EPAR for Sepioglin can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Sepioglini kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: It is used in addition to diet and exercise.
Estonian: Seda kasutatakse koos dieedi ja füüsilise koormusega.
English: The recommended starting dose of Sepioglin is 15 or 30 mg once a day.
Estonian: Sepioglini soovitatav algannus on 15 või 30 mg üks kord ööpäevas.
English: Treatment with Sepioglin should be reviewed after three to six months, and discontinued in patients who are not deriving sufficient benefit.
Estonian: Sepioglini ravivastus tuleb 3-6 kuu möödudes läbi vaadata ning lõpetada ravi patsientidel, kes ei saa ravist piisavalt kasu.
English: The Committee recommended that Sepioglin be given marketing authorisation.
Estonian: Komitee soovitas anda Sepioglini müügiloa.
English: This dose may need to be increased after one or two weeks to up to 45 mg once a day if better blood glucose (sugar) control is needed.
Estonian: Ühe või kahe nädala pärast tohib annust suurendada annuseni 45 mg ööpäevas, kui on vaja vere glükoosisisaldust paremini reguleerida.
English: The active substance in Sepioglin, pioglitazone, makes cells (fat, muscle and liver) more sensitive to insulin, which means that the body makes better use of the insulin it produces.
Estonian: Sepioglini toimeaine pioglitasoon suurendab rakkude (rasva-, lihas- ja maksarakud) tundlikkust insuliini suhtes, mis tähendab, et organism kasutab enda toodetavat insuliini paremini ära.
English: This is a summary of the European public assessment report (EPAR) for Sepioglin.
Estonian: See on ravimi Sepioglin Euroopa avaliku hindamisaruande kokkuvõte.
English: Other information about Sepioglin
Estonian: Muu teave Sepioglini kohta
English: For more information about treatment with Sepioglin, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Sepiogliniga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Sepioglin.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: EPAR summary for the public pioglitazone
Estonian: Kokkuvõte üldsusele pioglitasoon
English: Sepioglin is a ‘generic medicine'.
Estonian: Sepioglin on geneeriline ravim.
English: At subsequent reviews prescribers should confirm that benefits to patients are maintained.
Estonian: Järgmistel läbivaatamistel peab ravi määranud arst veenduma, et ravi kasulikkus püsib.
English: Because Sepioglin is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Sepioglin on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: The CHMP concluded that, in accordance with EU requirements, Sepioglin has been shown to have comparable quality and to be bioequivalent to Actos.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud Sepioglini võrdväärne kvaliteet ja bioekvivalentsus ravimiga Actos.
English: Because Sepioglin is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Actos.
Estonian: Et Sepioglin on geneeriline ravim, piirdusid patsiendiuuringud katsetega, milles näidati ravimi bioekvivalentsust võrdlusravimiga Actos.
English: This means that Sepioglin is similar to a ‘reference medicine' already authorised in the European Union (EU) called Actos.
Estonian: See tähendab, et Sepioglin on sarnane võrdlusravimiga Actos, millel juba on Euroopa Liidus müügiluba.
English: Sepioglin is used to treat type 2 diabetes in adults (aged 18 years or over), particularly those who are overweight.
Estonian: Sepioglini kasutatakse eelkõige ülekaaluliste täiskasvanud (vähemalt 18-aastaste) patsientide II tüüpi diabeedi (suhkurtõve) raviks.
English: Sepioglin is a medicine that contains the active substance pioglitazone.
Estonian: Sepioglin on ravim, mis sisaldab toimeainena pioglitasooni.
English: What is Sepioglin?
Estonian: Mis on Sepioglin?
English: Why has Sepioglin been approved?
Estonian: Miks Sepioglin heaks kiideti?
English: Therefore, the CHMP's view was that, as for Actos, the benefit outweighs the identified risk.
Estonian: Seetõttu arvas inimravimite komitee, et nagu ka Actose korral, ületab Sepioglini kasulikkus sellega kaasnevad riskid.
English: What are the benefits and risks of Sepioglin?
Estonian: Milles seisneb Sepioglini kasulikkus ja mis riskid ravimiga kaasnevad?
English: Sepioglin can also be used together with insulin in patients who are not satisfactorily controlled with insulin alone and cannot take metformin.
Estonian: Sepioglini tohib kasutada ka koos insuliiniga patsientidel, kellele üksnes insuliini manustamine ei mõju piisavalt ja kes ei saa kasutada metformiini.
English: Sepioglin should not be used in patients on dialysis (a blood clearance technique used in people with kidney disease).
Estonian: Sepioglinit ei tohi kasutada patsiendid, kes saavad dialüüsi (teatud verepuhastustehnika neeruhaiguste korral).
English: Sepioglin can also be used in combination with metformin in patients who are not satisfactorily controlled on metformin alone, or with a sulphonylurea (another type of antidiabetes medicine) when metformin is not suitable (‘dual therapy').
Estonian: Sepioglini tohib kasutada ka koos metformiiniga patsientidel, kelle haigus ainult metformiini kasutamisel rahuldavalt ravile ei allu, või koos sulfonüüluurearavimiga (samuti diabeediravim), kui metformiini ei saa kasutada (ravi kahe preparaadiga).
English: How does Sepioglin work?
Estonian: Kuidas Sepioglin toimib?
English: What is Sepioglin used for?
Estonian: Milleks Sepioglini kasutatakse?
English: How is Sepioglin used?
Estonian: Kuidas Sepioglini kasutatakse?
English: Sepioglin can also be used together with both metformin and a sulphonylurea in patients who are not satisfactorily controlled despite dual therapy by mouth (‘triple therapy').
Estonian: Sepioglini tohib kasutada koos metformiini ja sulfonüüluurearavimiga patsientidel, kelle haigus ei allu piisavalt suukaudsele ravile kahe preparaadiga (ravi kolme preparaadiga).
English: Sepioglin is used on its own in patients for whom metformin (another antidiabetes medicine) is not suitable.
Estonian: Sepioglini kasutatakse ainsa ravimina patsientidel, kellele ei sobi metformiin (samuti diabeediravim).
English: How has Sepioglin been studied?
Estonian: Kuidas Sepioglini uuriti?
English: (Invented) name Strength Pharmaceutical Form Route of Administration
Estonian: Müügiloa nr Euroopa Liidus Ravimi väljamõeldud nimetus Tugevus Ravimvorm Manustamistee Pakendi iseloomustus Pakendi suurus EU/1/09/592/001
English: 1 pre-filled pen + 1 pre-filled pen
Estonian: 1 eeltäidetud pensüstel + 1 eeltäidetud pensüstel
English: This summary was last updated in 09-2015.
Estonian: Kokkuvõte viimane uuendus: 09-2015.
English: BeneFIX is intended for either short-term or long-term use.
Estonian: BeneFIX on ette nähtud lühiajaliseks või pikaajaliseks kasutamiseks.
English: The European Commission granted a marketing authorisation valid throughout the European Union for BeneFIX on 27 August 1997.
Estonian: Euroopa Komisjon andis BeneFIXi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 27. augustil
English: A risk management plan has been developed to ensure that BeneFIX is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada BeneFIXi võimalikult ohutu kasutamine.
English: The full EPAR for BeneFIX can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst BeneFIXi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: What measures are being taken to ensure the safe and effective use of BeneFIX?
Estonian: Mis meetmed võetakse, et tagada BeneFIXi ohutu ja efektiivne kasutamine?
English: Out of 972 infusions, 84% were rated as bringing about ‘good' or ‘excellent' responses.
Estonian: 972 infusioonist hinnati 84% ravivastus „heaks” või „väga heaks”.
English: During treatment, the doctor should regularly carry out blood tests to adjust the dose to be given.
Estonian: Arst peab ravi ajal tegema korrapäraselt vereanalüüse, et kohandada ravimiannust.
English: Other information about BeneFIX
Estonian: Muu teave BeneFIXi kohta
English: In previously treated patients, 82% of the 693 bleeding episodes treated resolved after a single infusion of BeneFIX.
Estonian: Varem ravitud patsientidel tekkis ravivastus 693 veritsusjuhust 82% ainsa BeneFIXi infusiooni järel.
English: They include angioedema (swelling of the face and limbs), burning and stinging at the injection site, chills, flushing, urticaria (itchy rash), headache, hives, hypotension (low blood pressure), lethargy, nausea (feeling sick), restlessness, tachycardia (fast heartbeat), tightness of the chest, tingling, vomiting and wheezing.
Estonian: Need reaktsioonid on näiteks angioödeem (näo ja jäsemete turse), põletus- ja kipitustunne süstekohal, külmavärinad, õhetus, urtikaaria (sügelev lööve), peavalu, nõgeslööve, madal vererõhk, loidus, iiveldus, rahutus, tahhükardia (kiirenenud südametegevus), rõhumistunne rinnus, kirvendus, oksendamine ja vilistav hingamine.